909 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Proficio Capital Partners LLC

Proficio Capital Partners LLC bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 909 shares of the biopharmaceutical company’s stock, valued at approximately $567,000.

Several other hedge funds have also made changes to their positions in the company. BlackRock Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $5,682,636,000. Norges Bank bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $1,012,296,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Regeneron Pharmaceuticals by 142.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock valued at $1,504,991,000 after acquiring an additional 1,144,887 shares in the last quarter. Nuveen LLC lifted its stake in Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after acquiring an additional 835,240 shares during the period. Finally, Legal & General Group Plc bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth about $473,872,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Huda Y. Zoghbi sold 800 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. This represents a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the transaction, the director directly owned 603 shares of the company’s stock, valued at $482,400. The trade was a 39.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,400 shares of company stock worth $1,090,030 over the last 90 days. 6.97% of the stock is currently owned by corporate insiders.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder that causes abnormal bone formation and progressive loss of movement. Approval gives Regeneron a new commercial product and strengthens its rare-disease portfolio. However, the small patient population may limit its immediate contribution to earnings. Can Regeneron’s Rare-Disease Win Move the Earnings Needle?
• Neutral Sentiment: A Sound Shore Management investor letter highlighted Regeneron’s need to adjust its strategy following mixed results in melanoma drug trials. The commentary reflects ongoing investor debate about the company’s pipeline and long-term growth, while other market coverage indicates Wall Street remains reasonably constructive on the broader outlook. Regeneron Adjusts Course Amid Mixed Results in Melanoma Drug Trials
• Negative Sentiment: Multiple law firms announced or promoted a securities class action concerning allegations that Regeneron misled investors about the prospects of the Phase 3 Fianlimab-Libtayo trial for advanced melanoma. The trial failure reportedly caused a major selloff and an approximately $11 billion decline in market capitalization. The allegations have not been proven, but the litigation adds reputational, legal, and disclosure risk; the lead-plaintiff deadline is September 14, 2026. Regeneron Investors Have Opportunity to Lead Class Action Lawsuit

Regeneron Pharmaceuticals Stock Down 0.9%

Regeneron Pharmaceuticals stock opened at $807.71 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $847.00. The business has a fifty day moving average price of $713.83 and a 200-day moving average price of $717.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The stock has a market capitalization of $83.16 billion, a price-to-earnings ratio of 19.96, a PEG ratio of 1.39 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same period in the prior year, the company posted $12.81 EPS. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 9.29%.

Analysts Set New Price Targets

A number of research analysts have commented on REGN shares. Cantor Fitzgerald raised their target price on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Sanford C. Bernstein raised shares of Regeneron Pharmaceuticals to a “hold” rating in a report on Wednesday, July 29th. Truist Financial boosted their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, Leerink Partners upped their target price on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a report on Monday, August 17th. Fifteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $800.36.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.